Anti-SARS-CoV Envelope (CT)
| Code | Size | Price |
|---|
| LEI-S536-20ug | 20 ug | £199.00 |
Quantity:
| LEI-S536-0.1mg | 0.1 mg | £591.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Virus
Application: Enzyme-Linked Immunosorbent Assay (ELISA)
Shipping:
Ambient
Storage:
This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage aliquot in working volumes without diluting and store at -20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles.
Further Information
Concentration:
1.0 mg/ml
Conjugate/Tag/Label:
Purified No Carrier Protein
Format:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Formulation:
This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative.
Immunogen:
Anti-SARS-CoV Envelope antibody was raised against a peptide corresponding to 11 amino acids near the carboxy terminus of SARS-CoV Envelope protein. The immunogen is located within the last 50 amino acids of SARS-CoV Envelope.
Long Description:
A coronavirus, SARS (Severe Acute Respiratory Syndrome), was first identified 2002-2003. Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.
Target:
SARS E
References
1. Marra, M. A. et al. (2003) Science 300:1399
2. Rota, P. A. et al. (2003) Science 300:1394
3. Navas-Nartin, S. R. et al. (2004) J. Neurovirol. 10:75
4. Arbely, E. et al. (2004) J. Mol. Biol. 3414:769
Related Products
| Product Name | Product Code | Supplier | Anti-SARS-CoV-2 Envelope (NT) | LEI-S537 | Leinco Technologies | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Severe Acute Respiratory Syndrome E (CT) Blocking Peptide | LEI-S545 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Severe Acute Respiratory Syndrome E (NT) Blocking Peptide | LEI-S546 | Leinco Technologies | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||